Evicenter
P&T meetings

Relutrigine

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Regulatory submission
NDA submitted in early 2026
Launch
Not announced
Last updated
72 sources

Product information and disease descriptionProduct description

Product information

22 evidence topics · 16 sources

Average sales price and wholesale acquisition cost
Product price and anticipated annual cost per patient

Not applicable.

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information, contraindications, boxed warnings, and REMS

Not applicable.

Effect of Relutrigine on quality measures

No evidence found.